期刊文献+

丹参酮Ⅱ_A聚乳酸载药纳米粒体内药物分布初步研究 被引量:7

Study on the Pharmacokinetics of Tashinone Ⅱ_A-loaded Polylactic Acid Nanoparticles in Rabbit
下载PDF
导出
摘要 目的:建立测定兔体内丹参酮ⅡA的HPLC方法,并考察丹参酮ⅡA聚乳酸载药纳米粒(TS-PLA-NP)兔体内药代动力学特征。方法:家兔耳缘静脉注射TS-PLA-NP和丹参酮ⅡA溶液,在设定时间点从颈静脉取血制样,以吉非罗齐为内标,采用HPLC-MS法测定丹参酮ⅡA在兔体内的血药浓度及药物组织分布,药动学参数采用DAS2.0进行统计。结果:吉非罗齐和丹参酮ⅡA在该条件下的保留时间分别为10.5、14.5 min。TS-PLA-NP在家兔体内的t1/2由丹参酮ⅡA的2.573 h延长到4.117 h;MRT0~∞由2.585 h延长到6.033 h,峰浓度由0.21 mg/L减少到0.134 mg/L。静脉给药后2 h,丹参酮ⅡA纳米药物组肝脏和肿瘤中的浓度均高于丹参酮ⅡA组;丹参酮ⅡA以纳米的剂型给药后2 h,肝脏中的药物浓度提高了5倍以上,肿瘤中的药物浓度提高了近9倍;心、肾、脾、肺等组织中药物浓度均明显降低;血液中浓度下降了近10倍。结论:丹参酮ⅡA聚乳酸载药纳米粒在兔体内具有良好的缓释和肝靶向特征。 Objective:To establish a HPLC method for measuring tashinone Ⅱ_A concentration in rabbit plasma and study the pharmacokinetics of tashinone Ⅱ_A-loaded polylactic acid nanoparticles and tashinone Ⅱ_A injection in rabbits.Methods:A single dose of TS-PLA-NP and TSⅡ_A injection was administered to 8 healthy rabbits via the ear-edge vein,at the set time withdrew the blood and prepared.The concentrations of tashinone Ⅱ_A in plasma were measured by HPLC with gemfibrozil as the internal standard.The pharmacokinetic parameters of TS-PLA-NP and tashinone Ⅱ_A injection were calculated by program DAS2.0.Results:The average retention times of gemfibrozil and tashinone Ⅱ_A were 10.5 and 14.5 min,respectively.The half-life was prolonged from 2.573 h of free tashinone Ⅱ_A to 4.117 h and MRT_0~∞ from 2.585 h to 6.033 h.The max concentration of tashinone Ⅱ_A was reduced from 0.21 to 0.134 mg/L.Conclusion:The method for the pharmacokinetic research of tshinone Ⅱ_A in rabbit plasma is accuracy,rapid and sensitive.TS-PLA-NP shows significant characteristic of delayed-release.
出处 《中药材》 CAS CSCD 北大核心 2011年第9期1392-1395,共4页 Journal of Chinese Medicinal Materials
基金 国家自然基金(81001594) 上海市卫生局青年基金资助项目(S30302) 上海市重点学科资助项目(2009Y91) 上海市普陀区科技创新项目(20092010)
关键词 丹参酮ⅡA 聚乳酸纳米粒 HPLC-MS 内标法 药动学 Tashinone Ⅱ_A Polylactic acid Nanoparticles HPLC-MS Internal standard Pharmacokinetics
  • 相关文献

参考文献10

  • 1袁淑兰,王修杰,魏于全.丹参酮抗肿瘤作用及其机理的研究[J].癌症,2003,22(12):1363-1366. 被引量:49
  • 2Qi Li, Yan Wang ( co-author), Nianping Feng, et al. Novel polymeric Nanoparticles containing Tanshione I1 s for the treatment of Hepatoma[ J]. J Drug Target,2008,16(10) :725-732.
  • 3王炎,李琦,范忠泽,孙珏,王忆勤,刘瑞海,高虹.丹参酮ⅡA介导p38MAPK信号转导诱导人肝癌细胞凋亡[J].世界华人消化杂志,2009,17(2):124-129. 被引量:28
  • 4Lee KH, Liapi E, Buijs M,et al. Considerations for implan- tation site of VX2 carcinoma into rabbit liver [ J ]. J Vasc Interv Radiol, 2009,20 ( 1 ) : 113-117.
  • 5Morin C, Barratt G, Fessi H, et al. Improved intracellular delivery of a muramyl dipeptide analog by means of nano- capsules [J]. Int J Immunopharmacol, 1994, 16 (5-6) :451 -456.
  • 6Barratt G, Puisieux F, Yu WP,et al. Antimetastatic activity of mdp-l-alanyl-cholesterol incorporated into various types of nanocapsules [ J ]. Int J Immunopharmacol, 1994,16 ( 5-6) :457-461.
  • 7Lambert G, Fattal E, Pinto Alphandary H,et al. Poly-isobu- tylcyanoacrylate nanocapsules containing an aqueos core as a novel colloidal carrier for the delivery of oligonucleotides[J]. Pharm Res ,2000 ,17 : 707 -713.
  • 8Leroux JC, Allamann E, Dedaeghere E, et al. Biodegrable nanoparticles from sustained release formulations to im- proved site specific drug delivery [ J ]. Control Release,1996,39:339.
  • 9Jodan A, Wust P, Scholz R,et al. Effects of magnetic fluid hyperthermia(MFH) on C3H mannary carcinoma in vivo [ J]. Int J Hyperthermia, 1997,13:587-605.
  • 10Jodan A, Wust P, Scholz R,et al. Cellular uptake of mag- netic fluid particles and their effects on human adenocar- cinoma cells exposed to AC magnetic fields in vitro [ J ].Int J Hyperthermia, 1996,12:705-722.

二级参考文献38

共引文献74

同被引文献130

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部